FOXX:NASDAQFoxx Development Holdings Inc. Analysis
Data as of 2026-05-20 - not real-time
$3.85
Latest Price
8/10Risk
Risk Level: High
Executive Summary
The stock is trading at $3.85, sitting at the calculated support level of $3.85 and well below the DCF fair value of $5.90, indicating a potential undervaluation. The 20‑day SMA ($4.95) and 50‑day SMA ($4.92) sit above the current price, while the 200‑day SMA ($4.78) is also higher, confirming a short‑term price compression. Technical momentum is mixed: RSI is deep in oversold territory at 24.9, suggesting a possible rebound, but the MACD histogram is negative and the signal line is bearish, warning of lingering downside pressure. Volume is increasing, providing some liquidity support, yet the 30‑day volatility is extreme at 69% and beta of 1.48 signals high market sensitivity. Fundamental metrics are weak – revenue is declining 4.4%, margins are negative, and the company reports a -78% max drawdown, underscoring financial fragility. However, recent news notes that FOXX regained Nasdaq compliance and insiders have boosted their holdings by 122%, which may reflect renewed confidence.
Given the stark contrast between the low price and the DCF estimate, the stock leans toward a value play, but the combination of negative earnings, high volatility, and a thin market cap keeps the risk profile elevated. The lack of dividend and a negative book value further limit defensive appeal. Overall, the picture is one of a speculative upside opportunity tempered by substantial downside risk, suggesting a cautious stance.
Given the stark contrast between the low price and the DCF estimate, the stock leans toward a value play, but the combination of negative earnings, high volatility, and a thin market cap keeps the risk profile elevated. The lack of dividend and a negative book value further limit defensive appeal. Overall, the picture is one of a speculative upside opportunity tempered by substantial downside risk, suggesting a cautious stance.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- RSI indicating oversold conditions
- Price at technical support level
- Bearish MACD histogram
Medium Term
1–3 yearsNeutral
Model confidence: 4/10
Key Factors
- DCF fair value suggests upside
- Negative earnings and high volatility
- Insider buying signals confidence
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- Regained Nasdaq compliance
- Potential turnaround from value gap
- Long‑run industry PE average high, offering relative cheapness
Key Metrics & Analysis
Financial Health
Revenue Growth-4.40%
Profit Margin-24.62%
ROA-14.81%
P/B Ratio-2.3
Op. Cash Flow$-2177478
Free Cash Flow$4.7M
Industry P/E38.0
Technical Analysis
TrendBullish
RSI24.9
Support$3.85
Resistance$5.90
MA 20$4.95
MA 50$4.92
MA 200$4.78
MACDBearish
VolumeIncreasing
Fear & Greed Index89.16
Valuation
Fair Value$5.90
GradeUndervalued
TypeValue
Risk Assessment
Beta1.48
Volatility69.15%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.